全球可穿戴注射器市场 – 行业趋势及 2031 年预测

可穿戴注射器市场分析和规模

随着技术进步，可穿戴注射器市场持续蓬勃发展，为药物输送提供了显著优势。这些设备可以方便、精确地给药，彻底改变了患者护理。其紧凑的设计和用户友好的功能提高了便携性和依从性，使患有慢性疾病的人能够有效地管理自己的健康，标志着医疗治疗的范式转变。 

2023 年全球可穿戴注射器市场规模为 72.7 亿美元，预计到 2031 年将达到 156.9 亿美元，预测期内（2024 年至 2031 年）的复合年增长率为 10.1%。这表明市场价值。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

市场定义

Wearable injectors are portable medical devices designed to administer medication through subcutaneous or intramuscular injection. They are worn directly on the body, providing convenience and discretion for patients requiring regular injections, such as those with chronic conditions such as diabetes or autoimmune disorders. These devices offer precise dosing and can improve treatment adherence and patient outcomes.           

Wearable Injectors Market Dynamics

Drivers

• Rise in Chronic Diseases

The surge in chronic diseases such as diabetes, cardiovascular ailments, and autoimmune disorders demands consistent medication administration. Wearable injectors offer a user-friendly approach to delivering these medications, fueling market expansion. For instance, diabetic patients requiring frequent insulin injections find wearable injectors such as Insulet's Omnipod convenient. These devices enable discreet, on-the-go insulin delivery without the hassle of traditional injections, empowering patients to manage their condition effectively while maintaining an active lifestyle.

• Preference for Home Healthcare

The rising preference for home healthcare underscores a shift towards patient-centric approaches. Wearable injectors cater to this trend by empowering patients to self-administer medication conveniently at home. This enhances patient comfort and lowers healthcare expenses linked to hospital visits, aligning with the evolving landscape of self-management and cost-effective healthcare solutions.

Opportunities

• Drug Development Pipeline

The increasing number of biologic drugs, often necessitating subcutaneous administration, drives demand for wearable injectors. Biologics often mandate larger volumes and frequent injections. For instance, monoclonal antibodies such as medications such as monoclonal antibodies, insulin for diabetes management, and growth factors for certain cancers all benefit from wearable injectors, ensuring precise delivery and enhanced patient compliance in long-term treatment regimens.

• Focus on Patient Outcomes

Healthcare providers prioritize patient outcomes and treatment adherence. Wearable injectors, with features such as dose reminders, tracking, and connectivity to healthcare providers, facilitate better compliance. These devices empower patients to manage their medication effectively, improving treatment outcomes.

Restraints/Challenges

• Data Security and Privacy Concerns

Wearable injectors with integrated data connectivity for monitoring raise privacy concerns, necessitating robust cybersecurity measures. Protecting patient data from breaches is paramount, requiring stringent safeguards against unauthorized access or misuse. These measures ensure confidentiality and trust in these medical devices, maintaining patient privacy and safeguarding sensitive health information against potential security threats in the digital healthcare landscape. 

• High Cost of Development

The market faces hurdles due to high initial development, manufacturing, and deployment costs. This may hinder adoption, particularly in less affluent regions or healthcare systems, where budget constraints are prevalent, highlighting the need for cost-effective solutions to improve accessibility and expand the market reach. 

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2023, Enable Injections, Inc. forged a partnership with Viridian Therapeutics, Inc., a U.S.-based biotech firm, expanding collaborative efforts
•  In 2023, Tandem Diabetes Care, Inc. finalized the acquisition of AMF Medical SA, known for producing the Sigi Patch Pump, bolstering its portfolio
• In 2022, AbbVie gained US FDA approval for SKYRIZI, an interleukin-23 inhibitor, for treating moderately to severely active Crohn's disease. Administered via subcutaneous injection, it offers patients a self-administration option with an On-Body Injector
• In 2022, Enable Injections secured a USD 215 million funding round to advance enFuse, its subcutaneous drug delivery system. Comprising a wearable delivery disc and a vessel transfer system, enFuse promises enhanced drug delivery
• In 2020, Insulet Corporation, known for its Omnipod Insulin Management System, extended financial aid to its U.S. customers affected by the pandemic. Eligible customers could receive up to a six-month supply of products free of charge, easing financial burdens

Wearable Injectors Market Scope

The market is segmented on the basis of type, therapy, technology, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• On-Body
• Off-Body

Therapy

• Immuno-Oncology
• Diabetes
• Cardiovascular Diseases
• Parkinson's Disease
• Thalassemia
• Primary Immunodeficiency Disease

Technology

• Spring-based
• Motor-driven

End-Use

• Hospitals
• Clinics
• Homecare
• Others

Wearable Injectors Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, type, therapy, technology, and end-user as referenced above.

市场报告涉及的国家包括美国、加拿大、墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲其他地区、巴西、阿根廷和南美洲其他地区。

受慢性疾病增加、医疗基础设施先进以及大容量注射器易得等因素的推动，北美有望主导可穿戴注射器市场。该地区在采用方面处于领先地位，得益于可及性和技术进步，并促进了市场增长。

亚太地区可穿戴注射器市场呈现正增长态势，这归因于人们对超大容量设备的认识不断提高。政府对医疗设备的优惠措施进一步推动了市场扩张，尤其有利于该地区医疗保健行业采用可穿戴注射器。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

医疗保健基础设施增长安装基础和新技术渗透

该市场还为您提供每个国家/地区资本设备医疗支出增长、市场上不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对市场的影响的详细市场分析。数据适用于 2016-2021 年的历史时期。

竞争格局和可穿戴注射器市场份额分析

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

市场上的一些主要参与者包括：

• BD（美国）
• Ypsomed（瑞士）
• 安进公司 (美国)
• 子主题 Aps（丹麦）
• 启用注射（美国）
•  美敦力（爱尔兰）
• Insulet Corporation（美国）
• 联合治疗公司 (美国)
• CeQur Simplicity（瑞士）
• Gerresheimer AG（瑞士）
• West Pharmaceutical Services, Inc.（美国）
• Sonceboz（瑞士）
• Elcam 药物输送设备（以色列）
• Recipharm AB.（英国）
• 斯蒂瓦那托集团（意大利）
• Sorrel Medical（以色列）
• Weibel CDS AG（瑞士）

SKU-68241